The combined effect of lifestyle factors and polygenic scores on age at onset in Parkinson's disease.
GBA1
Caffeine
Gene-environment
NSAID
Smoking
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 06 2024
25 06 2024
Historique:
received:
08
02
2024
accepted:
21
06
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
25
6
2024
Statut:
epublish
Résumé
The objective of this study was to investigate the association between a Parkinson's disease (PD)-specific polygenic score (PGS) and protective lifestyle factors on age at onset (AAO) in PD. We included data from 4367 patients with idiopathic PD, 159 patients with GBA1-PD, and 3090 healthy controls of European ancestry from AMP-PD, PPMI, and Fox Insight cohorts. The association between PGS and lifestyle factors on AAO was assessed with linear and Cox proportional hazards models. The PGS showed a negative association with AAO (β = - 1.07, p = 6 × 10
Identifiants
pubmed: 38918550
doi: 10.1038/s41598-024-65640-x
pii: 10.1038/s41598-024-65640-x
doi:
Substances chimiques
Glucosylceramidase
EC 3.2.1.45
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14670Subventions
Organisme : Michael J. Fox Foundation for Parkinson's Research
ID : MJFF-019271
Organisme : Michael J. Fox Foundation for Parkinson's Research
ID : MJFF-021227
Organisme : Deutsche Forschungsgemeinschaft
ID : FOR2488
Informations de copyright
© 2024. The Author(s).
Références
Jia, F., Fellner, A. & Kumar, K. R. Monogenic Parkinson’s disease: Genotype, phenotype, pathophysiology, and genetic testing. Genes (Basel) https://doi.org/10.3390/genes13030471 (2022).
doi: 10.3390/genes13030471
pubmed: 36672850
pmcid: 9777934
Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: A meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091–1102. https://doi.org/10.1016/S1474-4422(19)30320-5 (2019).
doi: 10.1016/S1474-4422(19)30320-5
pubmed: 31701892
pmcid: 8422160
Chang, D. et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat. Genet. 49, 1511–1516. https://doi.org/10.1038/ng.3955 (2017).
doi: 10.1038/ng.3955
pubmed: 28892059
pmcid: 5812477
Koch, S. et al. Validity and prognostic value of a polygenic risk score for Parkinson’s disease. Genes (Basel) https://doi.org/10.3390/genes12121859 (2021).
doi: 10.3390/genes12121859
pubmed: 34946808
pmcid: 8525676
Li, W. W. et al. Association of the Polygenic risk score with the incidence risk of Parkinson’s disease and cerebrospinal fluid alpha-synuclein in a Chinese cohort. Neurotox. Res. 36, 515–522. https://doi.org/10.1007/s12640-019-00066-2 (2019).
doi: 10.1007/s12640-019-00066-2
pubmed: 31209785
Reynoso, A. et al. Gene-environment interactions for Parkinson’s disease. Ann. Neurol. https://doi.org/10.1002/ana.26852 (2023).
doi: 10.1002/ana.26852
Huang, Y. et al. Risk factors associated with age at onset of Parkinson’s disease in the UK Biobank. NPJ Parkinsons Dis. 10, 3. https://doi.org/10.1038/s41531-023-00623-9 (2024).
doi: 10.1038/s41531-023-00623-9
pubmed: 38167894
pmcid: 10762149
Jacobs, B. M. et al. Parkinson’s disease determinants, prediction and gene-environment interactions in the UK Biobank. J. Neurol. Neurosurg. Psychiatry 91, 1046–1054. https://doi.org/10.1136/jnnp-2020-323646 (2020).
doi: 10.1136/jnnp-2020-323646
pubmed: 32934108
Paul, K. C., Schulz, J., Bronstein, J. M., Lill, C. M. & Ritz, B. R. Association of polygenic risk score with cognitive decline and motor progression in Parkinson disease. JAMA Neurol. 75, 360–366. https://doi.org/10.1001/jamaneurol.2017.4206 (2018).
doi: 10.1001/jamaneurol.2017.4206
pubmed: 29340614
pmcid: 5885856
Pavelka, L. et al. Age at onset as stratifier in idiopathic Parkinson’s disease—effect of ageing and polygenic risk score on clinical phenotypes. NPJ Parkinsons Dis. 8, 102. https://doi.org/10.1038/s41531-022-00342-7 (2022).
doi: 10.1038/s41531-022-00342-7
pubmed: 35945230
pmcid: 9363416
Escott-Price, V. et al. Polygenic risk of Parkinson disease is correlated with disease age at onset. Ann. Neurol. 77, 582–591. https://doi.org/10.1002/ana.24335 (2015).
doi: 10.1002/ana.24335
pubmed: 25773351
pmcid: 4737223
Han, Y. et al. Genome-wide polygenic risk score identifies individuals at elevated Parkinson’s disease risk. medRxiv https://doi.org/10.1101/2020.10.16.20212944 (2020).
doi: 10.1101/2020.10.16.20212944
pubmed: 33336213
pmcid: 7745130
Ibanez, L. et al. Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. BMC Neurol. 17, 198. https://doi.org/10.1186/s12883-017-0978-z (2017).
doi: 10.1186/s12883-017-0978-z
pubmed: 29141588
pmcid: 5688622
Elbaz, A. et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson’s disease. Ann. Neurol. 55, 430–434. https://doi.org/10.1002/ana.20051 (2004).
doi: 10.1002/ana.20051
pubmed: 14991823
Fitzmaurice, A. G., Rhodes, S. L., Cockburn, M., Ritz, B. & Bronstein, J. M. Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease. Neurology 82, 419–426. https://doi.org/10.1212/WNL.0000000000000083 (2014).
doi: 10.1212/WNL.0000000000000083
pubmed: 24491970
pmcid: 3917685
Gamache, P. L. et al. Exposure to pesticides and welding hastens the age-at-onset of Parkinson’s disease. Can. J. Neurol. Sci. 46, 711–716. https://doi.org/10.1017/cjn.2019.248 (2019).
doi: 10.1017/cjn.2019.248
pubmed: 31342891
Ratner, M. H., Farb, D. H., Ozer, J., Feldman, R. G. & Durso, R. Younger age at onset of sporadic Parkinson’s disease among subjects occupationally exposed to metals and pesticides. Interdiscip. Toxicol. 7, 123–133. https://doi.org/10.2478/intox-2014-0017 (2014).
doi: 10.2478/intox-2014-0017
pubmed: 26109889
pmcid: 4434105
Jafari, S., Etminan, M., Aminzadeh, F. & Samii, A. Head injury and risk of Parkinson disease: A systematic review and meta-analysis. Mov. Disord. 28, 1222–1229. https://doi.org/10.1002/mds.25458 (2013).
doi: 10.1002/mds.25458
pubmed: 23609436
Aune, D. et al. Diabetes mellitus, prediabetes and the risk of Parkinson’s disease: A systematic review and meta-analysis of 15 cohort studies with 29.9 million participants and 86,345 cases. Eur. J. Epidemiol. 38, 591–604. https://doi.org/10.1007/s10654-023-00970-0 (2023).
doi: 10.1007/s10654-023-00970-0
pubmed: 37185794
pmcid: 10232631
Grover, S. et al. Risky behaviors and Parkinson disease: A mendelian randomization study. Neurology 93, e1412–e1424. https://doi.org/10.1212/WNL.0000000000008245 (2019).
doi: 10.1212/WNL.0000000000008245
pubmed: 31527283
pmcid: 7010323
Larsson, S. C. & Burgess, S. Appraising the causal role of smoking in multiple diseases: A systematic review and meta-analysis of Mendelian randomization studies. EBioMedicine 82, 104154. https://doi.org/10.1016/j.ebiom.2022.104154 (2022).
doi: 10.1016/j.ebiom.2022.104154
pubmed: 35816897
pmcid: 9278068
Noyce, A. J. et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann. Neurol. 72, 893–901. https://doi.org/10.1002/ana.23687 (2012).
doi: 10.1002/ana.23687
pubmed: 23071076
pmcid: 3556649
Fan, B. et al. What and how can physical activity prevention function on Parkinson’s disease?. Oxid. Med. Cell. Longev. 2020, 4293071. https://doi.org/10.1155/2020/4293071 (2020).
doi: 10.1155/2020/4293071
pubmed: 32215173
pmcid: 7042542
Casper, D., Yaparpalvi, U., Rempel, N. & Werner, P. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci. Lett. 289, 201–204. https://doi.org/10.1016/s0304-3940(00)01294-5 (2000).
doi: 10.1016/s0304-3940(00)01294-5
pubmed: 10961664
Marras, C., Canning, C. G. & Goldman, S. M. Environment, lifestyle, and Parkinson’s disease: Implications for prevention in the next decade. Mov. Disord. 34, 801–811. https://doi.org/10.1002/mds.27720 (2019).
doi: 10.1002/mds.27720
pubmed: 31091353
Delamarre, A. & Meissner, W. G. Epidemiology, environmental risk factors and genetics of Parkinson’s disease. Presse Med. 46, 175–181. https://doi.org/10.1016/j.lpm.2017.01.001 (2017).
doi: 10.1016/j.lpm.2017.01.001
pubmed: 28189372
Mappin-Kasirer, B. et al. Tobacco smoking and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors. Neurology 94, e2132–e2138. https://doi.org/10.1212/WNL.0000000000009437 (2020).
doi: 10.1212/WNL.0000000000009437
pubmed: 32371450
pmcid: 7526668
Wahner, A. D., Bronstein, J. M., Bordelon, Y. M. & Ritz, B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69, 1836–1842. https://doi.org/10.1212/01.wnl.0000279519.99344.ad (2007).
doi: 10.1212/01.wnl.0000279519.99344.ad
pubmed: 17984451
Heilbron, K. et al. Unhealthy behaviours and risk of Parkinson’s disease: A mendelian randomisation study. J. Parkinsons Dis. 11, 1981–1993. https://doi.org/10.3233/JPD-202487 (2021).
doi: 10.3233/JPD-202487
pubmed: 34275906
pmcid: 8609708
Hong, C. T., Chan, L. & Bai, C. H. The effect of caffeine on the risk and progression of Parkinson’s disease: A meta-analysis. Nutrients https://doi.org/10.3390/nu12061860 (2020).
doi: 10.3390/nu12061860
pubmed: 33348773
pmcid: 7766402
Domenighetti, C. et al. Mendelian randomisation study of smoking, alcohol, and coffee drinking in relation to Parkinson’s disease. J. Parkinsons Dis. 12, 267–282. https://doi.org/10.3233/JPD-212851 (2022).
doi: 10.3233/JPD-212851
pubmed: 34633332
pmcid: 9211765
Gabbert, C. et al. Coffee, smoking and aspirin are associated with age at onset in idiopathic Parkinson’s disease. J. Neurol. 269, 4195–4203. https://doi.org/10.1007/s00415-022-11041-x (2022).
doi: 10.1007/s00415-022-11041-x
pubmed: 35235000
pmcid: 9294004
Hamza, T. H. et al. Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson’s disease modifier gene via interaction with coffee. PLoS Genet. 7, e1002237. https://doi.org/10.1371/journal.pgen.1002237 (2011).
doi: 10.1371/journal.pgen.1002237
pubmed: 21876681
pmcid: 3158052
Chuang, Y. H. et al. Gene-environment interaction in Parkinson’s disease: Coffee, ADORA2A, and CYP1A2. Neuroepidemiology 47, 192–200. https://doi.org/10.1159/000450855 (2016).
doi: 10.1159/000450855
pubmed: 28135712
Lee, P. C. et al. Smoking and Parkinson disease: Evidence for gene-by-smoking interactions. Neurology 90, e583–e592. https://doi.org/10.1212/WNL.0000000000004953 (2018).
doi: 10.1212/WNL.0000000000004953
pubmed: 29352099
pmcid: 5818012
Chuang, Y. H. et al. Pooled analysis of the HLA-DRB1 by smoking interaction in Parkinson disease. Ann. Neurol. 82, 655–664. https://doi.org/10.1002/ana.25065 (2017).
doi: 10.1002/ana.25065
pubmed: 28981958
pmcid: 5798887
Luth, T. et al. Age at onset of LRRK2 p.Gly2019Ser is related to environmental and lifestyle factors. Mov. Disord. 35, 1854–1858. https://doi.org/10.1002/mds.28238 (2020).
doi: 10.1002/mds.28238
pubmed: 32875616
Wijeyekoon, R. et al. Associations between lifestyle factors and Parkinson’s Disease in an urban Sri Lankan clinic study. Int. Arch. Med. https://doi.org/10.3823/2516 (2017).
doi: 10.3823/2516
pubmed: 29057010
Wilk, J. B. & Lash, T. L. Risk factor studies of age-at-onset in a sample ascertained for Parkinson disease affected sibling pairs: A cautionary tale. Emerg. Themes Epidemiol. 4, 1. https://doi.org/10.1186/1742-7622-4-1 (2007).
doi: 10.1186/1742-7622-4-1
pubmed: 17408493
pmcid: 1855322
Yahalom, G. et al. Age at onset of Parkinson’s disease among Ashkenazi Jewish patients: Contribution of environmental factors, LRRK2 p.G2019S and GBA p.N370S mutations. J. Parkinsons Dis. 10, 1123–1132. https://doi.org/10.3233/JPD-191829 (2020).
doi: 10.3233/JPD-191829
pubmed: 32310186
De Reuck, J., De Weweire, M., Van Maele, G. & Santens, P. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson’s disease. J. Neurol. Sci. 231, 35–39. https://doi.org/10.1016/j.jns.2004.12.003 (2005).
doi: 10.1016/j.jns.2004.12.003
pubmed: 15792818
Gigante, A. F., Martino, T., Iliceto, G. & Defazio, G. Smoking and age-at-onset of both motor and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat. Disord. 45, 94–96. https://doi.org/10.1016/j.parkreldis.2017.09.022 (2017).
doi: 10.1016/j.parkreldis.2017.09.022
pubmed: 28988683
Gigante, A. F. et al. Chronic coffee consumption and striatal DAT-SPECT findings in Parkinson’s disease. Neurol. Sci. 39, 551–555. https://doi.org/10.1007/s10072-018-3253-1 (2018).
doi: 10.1007/s10072-018-3253-1
pubmed: 29362953
Rosas, I. et al. Smoking is associated with age at disease onset in Parkinson’s disease. Parkinsonism Relat. Disord. 97, 79–83. https://doi.org/10.1016/j.parkreldis.2022.03.005 (2022).
doi: 10.1016/j.parkreldis.2022.03.005
pubmed: 35364453
Kang, U. J. et al. The BioFIND study: Characteristics of a clinically typical Parkinson’s disease biomarker cohort. Mov. Disord. 31, 924–932. https://doi.org/10.1002/mds.26613 (2016).
doi: 10.1002/mds.26613
pubmed: 27113479
pmcid: 5021110
Mohammadi, D. The Harvard biomarker study’s big plan. Lancet Neurol. 12, 739–740. https://doi.org/10.1016/S1474-4422(13)70155-8 (2013).
doi: 10.1016/S1474-4422(13)70155-8
pubmed: 23809962
Chia, R. et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat. Genet. 53, 294–303. https://doi.org/10.1038/s41588-021-00785-3 (2021).
doi: 10.1038/s41588-021-00785-3
pubmed: 33589841
pmcid: 7946812
Marek, K. et al. The Parkinson’s progression markers initiative (PPMI)—establishing a PD biomarker cohort. Ann. Clin. Transl. Neurol. 5, 1460–1477. https://doi.org/10.1002/acn3.644 (2018).
doi: 10.1002/acn3.644
pubmed: 30564614
pmcid: 6292383
Holloway, R. et al. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson disease(STEADY-PD III): Baseline characteristics and study update. Mov. Disord. 33, S150–S150 (2018).
Smolensky, L. et al. Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson’s disease. Sci. Data 7, 67. https://doi.org/10.1038/s41597-020-0401-2 (2020).
doi: 10.1038/s41597-020-0401-2
pubmed: 32094335
pmcid: 7039948
Iwaki, H. et al. Accelerating medicines partnership: Parkinson’s disease. Genetic resource. Mov. Disord. 36, 1795–1804. https://doi.org/10.1002/mds.28549 (2021).
doi: 10.1002/mds.28549
pubmed: 33960523
pmcid: 8453903
Purcell, S. et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575. https://doi.org/10.1086/519795 (2007).
doi: 10.1086/519795
pubmed: 17701901
pmcid: 1950838
Arnold, M., Raffler, J., Pfeufer, A., Suhre, K. & Kastenmuller, G. SNiPA: An interactive, genetic variant-centered annotation browser. Bioinformatics 31, 1334–1336. https://doi.org/10.1093/bioinformatics/btu779 (2015).
doi: 10.1093/bioinformatics/btu779
pubmed: 25431330
Robin, X. et al. pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 12, 77. https://doi.org/10.1186/1471-2105-12-77 (2011).
doi: 10.1186/1471-2105-12-77
Wickham, H. Use R!, 1 online resource (XVI, 260 pages 232 illustrations, 140 illustrations in color (Springer International Publishing, 2016).
R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2023).
Checkoway, H. et al. Parkinson’s disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am. J. Epidemiol. 155, 732–738. https://doi.org/10.1093/aje/155.8.732 (2002).
doi: 10.1093/aje/155.8.732
pubmed: 11943691
Chen, H. et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann. Neurol. 58, 963–967. https://doi.org/10.1002/ana.20682 (2005).
doi: 10.1002/ana.20682
pubmed: 16240369
Poly, T. N., Islam, M. M. R., Yang, H. C. & Li, Y. J. Non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease in the elderly population: A meta-analysis. Eur. J. Clin. Pharmacol. 75, 99–108. https://doi.org/10.1007/s00228-018-2561-y (2019).
doi: 10.1007/s00228-018-2561-y
pubmed: 30280208
Becker, C., Jick, S. S. & Meier, C. R. NSAID use and risk of Parkinson disease: A population-based case-control study. Eur. J. Neurol. 18, 1336–1342. https://doi.org/10.1111/j.1468-1331.2011.03399.x (2011).
doi: 10.1111/j.1468-1331.2011.03399.x
pubmed: 21457177
Al-Azayzih, A. et al. Nonsteroidal anti-inflammatory drugs utilization patterns and risk of adverse events due to drug-drug interactions among elderly patients: A study from Jordan. Saudi Pharm. J. 28, 504–508. https://doi.org/10.1016/j.jsps.2020.03.001 (2020).
doi: 10.1016/j.jsps.2020.03.001
pubmed: 32273811
pmcid: 7132832
Liu, E. Y. et al. Use of preventive aspirin among older US adults with and without diabetes. JAMA Netw. Open 4, e2112210. https://doi.org/10.1001/jamanetworkopen.2021.12210 (2021).
doi: 10.1001/jamanetworkopen.2021.12210
pubmed: 34152419
pmcid: 8218072
Williams, C. D. et al. Aspirin use among adults in the U.S.: Results of a national survey. Am. J. Prev. Med. 48, 501–508. https://doi.org/10.1016/j.amepre.2014.11.005 (2015).
doi: 10.1016/j.amepre.2014.11.005
pubmed: 25891049
Pajares, M., I. Rojo, A., Manda, G., Boscá, L. & Cuadrado, A. Inflammation in Parkinson’s disease: Mechanisms and therapeutic implications. Cells https://doi.org/10.3390/cells9071687 (2020).
doi: 10.3390/cells9071687
pubmed: 32674367
pmcid: 7408280
Marogianni, C. et al. Neurodegeneration and inflammation-an interesting interplay in Parkinson’s disease. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21228421 (2020).
doi: 10.3390/ijms21228421
pubmed: 33182554
pmcid: 7697354
Thaler, A. et al. Mutations in GBA and LRRK2 are not associated with increased inflammatory markers. J. Parkinsons Dis. 11, 1285–1296. https://doi.org/10.3233/JPD-212624 (2021).
doi: 10.3233/JPD-212624
pubmed: 33998549
pmcid: 8461659
Lüth, T. et al. Interaction of mitochondrial polygenic score and environmental factors in LRRK2 p.Gly2019Ser parkinsonism. medRxiv https://doi.org/10.1101/2023.01.02.23284113 (2023).
doi: 10.1101/2023.01.02.23284113
pubmed: 37662355
pmcid: 10473779
Billingsley, K. J. et al. Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset. NPJ Parkinsons Dis. 5, 8. https://doi.org/10.1038/s41531-019-0080-x (2019).
doi: 10.1038/s41531-019-0080-x
pubmed: 31123700
pmcid: 6531455
Wojcik, G. L. et al. Genetic analyses of diverse populations improves discovery for complex traits. Nature 570, 514–518. https://doi.org/10.1038/s41586-019-1310-4 (2019).
doi: 10.1038/s41586-019-1310-4
pubmed: 31217584
pmcid: 6785182
Sirugo, G., Williams, S. M. & Tishkoff, S. A. The missing diversity in human genetic studies. Cell 177, 26–31. https://doi.org/10.1016/j.cell.2019.02.048 (2019).
doi: 10.1016/j.cell.2019.02.048
pubmed: 30901543
pmcid: 7380073
Caliebe, A. et al. Including diverse and admixed populations in genetic epidemiology research. Genet. Epidemiol. 46, 347–371. https://doi.org/10.1002/gepi.22492 (2022).
doi: 10.1002/gepi.22492
pubmed: 35842778
pmcid: 9452464